Evidence map›Paper›PMID 42026061›Full record

ArticleNature communications2026

Multiomics immune profiling of a patient-relevant orthotopic lung cancer model using SEPARATE-Seq.

Pauline M R Bardet, Lize Allonsius, Eva Hadadi, Daliya Kancheva, Morgane Paque, Sarka Vosahlikova, Aarushi A Caro, Anouk Van Audenhove, Ayla Debraekeleer, Ria Roelandt and 15 more

Abstract read
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Pauline M R Bardet *Laboratory of Dendritic Cell Biology and Cancer Immunotherapy, VIB Center for Inflammation Research, Brussels, Belgium.ORCID http://orcid.org/0000-0003-4454-9823
Lize Allonsius *Laboratory of Dendritic Cell Biology and Cancer Immunotherapy, VIB Center for Inflammation Research, Brussels, Belgium.ORCID http://orcid.org/0000-0002-4133-5021
Eva Hadadi *Laboratory of Dendritic Cell Biology and Cancer Immunotherapy, VIB Center for Inflammation Research, Brussels, Belgium.
Daliya KanchevaLaboratory of Dendritic Cell Biology and Cancer Immunotherapy, VIB Center for Inflammation Research, Brussels, Belgium.ORCID http://orcid.org/0000-0001-6222-0461
Morgane PaqueLaboratory of Cancer Signaling, GIGA-Institute, University of Liège, Liège, Belgium.
Sarka VosahlikovaSotio Biotech a.s., Prague, Czech Republic.
Aarushi A CaroLaboratory of Dendritic Cell Biology and Cancer Immunotherapy, VIB Center for Inflammation Research, Brussels, Belgium.
Anouk Van AudenhoveLaboratory of Dendritic Cell Biology and Cancer Immunotherapy, VIB Center for Inflammation Research, Brussels, Belgium.
Ayla DebraekeleerLaboratory of Dendritic Cell Biology and Cancer Immunotherapy, VIB Center for Inflammation Research, Brussels, Belgium.
Ria RoelandtVIB Single Cell Core, VIB, Ghent/Leuven, Belgium.
Kevin VerstaenVIB Single Cell Core, VIB, Ghent/Leuven, Belgium.ORCID http://orcid.org/0000-0003-3582-0298
Michal HenslerSotio Biotech a.s., Prague, Czech Republic.
Delphine HotonDepartment of Pathology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium.
Gisèle Mateu CabreraLaboratory of Dendritic Cell Biology and Cancer Immunotherapy, VIB Center for Inflammation Research, Brussels, Belgium.
Louis BoonJJP Biologics, Warsaw, Poland.ORCID http://orcid.org/0000-0002-0937-9171
Arnaud BlommeLaboratory of Cancer Signaling, GIGA-Institute, University of Liège, Liège, Belgium.ORCID http://orcid.org/0000-0003-4183-8726
Sofie DeschoemaekerLaboratory of Dendritic Cell Biology and Cancer Immunotherapy, VIB Center for Inflammation Research, Brussels, Belgium.ORCID http://orcid.org/0000-0001-5449-282X
Geert RaesLaboratory of Dendritic Cell Biology and Cancer Immunotherapy, VIB Center for Inflammation Research, Brussels, Belgium.
Elly MarcqLaboratory of Dendritic Cell Biology and Cancer Immunotherapy, VIB Center for Inflammation Research, Brussels, Belgium.
Ahmed E I HamoudaLaboratory of Dendritic Cell Biology and Cancer Immunotherapy, VIB Center for Inflammation Research, Brussels, Belgium.ORCID http://orcid.org/0000-0001-6532-9585
Jan P BöttcherDepartment of Experimental Immunology, Institute of Immunology, University of Tübingen, Tübingen, Germany.ORCID http://orcid.org/0000-0002-8163-8107
Jitka FucikovaSotio Biotech a.s., Prague, Czech Republic.ORCID http://orcid.org/0000-0002-8423-479X
Pierre CloseLaboratory of Cancer Signaling, GIGA-Institute, University of Liège, Liège, Belgium.ORCID http://orcid.org/0000-0002-8844-9616
Frank Aboubakar NanaInstitut de Duve, Université Catholique de Louvain, Brussels, Belgium.
Damya LaouiLaboratory of Dendritic Cell Biology and Cancer Immunotherapy, VIB Center for Inflammation Research, Brussels, Belgium. dlaoui@vub.be.ORCID http://orcid.org/0000-0002-3373-1403

Funding

Stichting Tegen Kanker (Belgian Foundation Against Cancer) 2021-023
6 · The paper itself

Abstract

Relevant pre-clinical models are essential for driving progress in cancer therapy research. Here, we develop a pre-clinical study framework using an injectable orthotopic lung adenocarcinoma (LUAD) model (ORTHO) that replicates key features of human LUAD patients and is dissectible into tumoural and non-tumoural adjacent tissue, in analogy with patient samples. We also present SEPARATE-Seq, a broadly applicable technique enabling the partitioning of vascular and intratissue immune cells along with scRNA-Seq. By applying both SEPARATE-Seq and spatial transcriptomics to our dissectible ORTHO model, we confirm that our model replicates key immune features of human LUAD patients. Similarly to these patients, we observe NK-cell dysfunction and neutrophil dichotomy, and show that these are affected by their vascular/intratissue or tumour/adjacent location, highlighting the need for these spatial distinctions. Additionally, we show that several immune populations are restricted to specialised, local niches within the tumour, including a ring of lipid-associated TAMs lining the tumour edge and hubs of interferon-stimulated cells. Overall, our resource, available through an interactive tool, provides a comprehensive multiomics immune characterisation of a reproducible pre-clinical LUAD mouse model.

Indexed as

Adenocarcinoma of LungLung NeoplasmsAnimalsCell Line, TumorDisease Models, AnimalFemaleGene Expression ProfilingHumansKiller Cells, NaturalMiceMultiomicsNeutrophilsSpatial TranscriptomicsTumor Microenvironment

Identifiers

PMID42026061
PMCPMC13315217

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.